Chinese Biotech's New GLP-1 Drug Shows Promise in Weight Loss Trials
TL;DR Summary
Hangzhou Sciwind Biosciences has developed ecnoglutide, a promising obesity drug that showed over 15% weight loss in late-stage trials, positioning it as a competitor to Eli Lilly's Zepbound and Novo Nordisk's Wegovy, with potential approval in China by 2026 and plans for international development.
- Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug Bloomberg.com
- China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds Reuters
- New weight-loss drug sails through all-important Phase III trial New Atlas
- Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss Medscape
- China, where obesity levels are low, becomes hotbed for weight loss drug trials STAT
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
92%
526 → 44 words
Want the full story? Read the original article
Read on Bloomberg.com